Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076160 · ClinicalTrials.gov registry record · NA
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
A NA study of Presbyopia and Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 74
- Enrollment target
- 7
- Study locations
NCT07076160: Completed NA study of Presbyopia and Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT07076160 is a NA study of Presbyopia and Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 74 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (72% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076160, a NA study of Presbyopia and Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a 6-visit, single-masked, multi-site, 2×3 crossover, randomized-controlled, dispensing clinical trial to evaluate visual acuity.
Primary Outcome
Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at distance (4 meters) using ETDRS Charts.
Conditions Studied
Interventions
- DEVICE INFUSE® One Day Multifocal
- DEVICE ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens
Study Locations (7)
Florida
- Dr. James Weber & Associates, PA - City Square Blvd - Jacksonville
- VRC - Jacksonville
- Pearson Research Center, PA - Longwood
- Maitland Vision Center - North Orlando Ave - Maitland
New York
- Sacco Eye Group - Vestal
Ohio
- Luxe Vision and Optical - Powell
Rhode Island
- Dr. David W. Ferris & Associates - Warwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2025-09-20 |
| Phase | NA |
What the finished NCT07076160 record still lists
NCT07076160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which INFUSE® One Day Multifocal is the first listed.
NCT07076160 lists 7 locations in 4 states (Florida, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT07076160 about?
NCT07076160 is a clinical study titled "Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses". This is a 6-visit, single-masked, multi-site, 2×3 crossover, randomized-controlled, dispensing clinical trial to evaluate visual acuity.
What is the current status of trial NCT07076160?
This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2025-07-24. Estimated completion is 2025-09-20.
What conditions does trial NCT07076160 study?
This clinical trial studies the following conditions: Presbyopia, Visual Acuity.
What interventions are being tested in trial NCT07076160?
The interventions under investigation include: INFUSE® One Day Multifocal (DEVICE), ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT07076160?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076160 being conducted?
This trial has 7 study locations across Florida, New York, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07076160's enrollment target sits among peer trials
74 21st of 38 higher than 18 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
-
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI